OncLive | Gilead Sciences Moves Ahead on Idelalisib Filings OncLive Combination treatment with idelalisib and rituximab (Rituxan) was associated with a >70% improvement in overall survival (OS) in patients with high-risk relapsed/refractory CLL, according to phase III data from Study 116 (Abstract LBA-6) presented at ... |
